Skip to main content
Top
Published in: Journal of Inflammation 1/2011

Open Access 01-12-2011 | Research

Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts

Authors: Linnéa Asp, Anne-Sofie Johansson, Amandeep Mann, Björn Owe-Larsson, Ewa M Urbanska, Tomasz Kocki, Magdalena Kegel, Göran Engberg, Gabriella BS Lundkvist, Håkan Karlsson

Published in: Journal of Inflammation | Issue 1/2011

Login to get access

Abstract

Background

The kynurenine pathway (KP) is the main route of tryptophan degradation in the human body and generates several neuroactive and immunomodulatory metabolites. Altered levels of KP-metabolites have been observed in neuropsychiatric and neurodegenerative disorders as well as in patients with affective disorders. The purpose of the present study was to investigate if skin derived human fibroblasts are useful for studies of expression of enzymes in the KP.

Methods

Fibroblast cultures were established from cutaneous biopsies taken from the arm of consenting volunteers. Such cultures were subsequently treated with interferon (IFN)-γ 200 U/ml and/or tumor necrosis factor (TNF)-α, 100 U/ml for 48 hours in serum-free medium. Levels of transcripts encoding different enzymes were determined by real-time PCR and levels of kynurenic acid (KYNA) were determined by HPLC.

Results

At base-line all cultures harbored detectable levels of transcripts encoding KP enzymes, albeit with considerable variation across individuals. Following cytokine treatment, considerable changes in many of the transcripts investigated were observed. For example, increases in the abundance of transcripts encoding indoleamine 2,3-dioxygenase, kynureninase or 3-hydroxyanthranilic acid oxygenase and decreases in the levels of transcripts encoding tryptophan 2,3-dioxygenase, kynurenine aminotransferases or quinolinic acid phosphoribosyltransferase were observed following IFN-γ and TNF-α treatment. Finally, the fibroblast cultures released detectable levels of KYNA in the cell culture medium at base-line conditions, which were increased after IFN-γ, but not TNF-α, treatments.

Conclusions

All of the investigated genes encoding KP enzymes were expressed in human fibroblasts. Expression of many of these appeared to be regulated in response to cytokine treatment as previously reported for other cell types. Fibroblast cultures, thus, appear to be useful for studies of disease-related abnormalities in the kynurenine pathway of tryptophan degradation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moffett JR, Namboodiri MA: Tryptophan and the immune response. Immunol Cell Biol. 2003, 81 (4): 247-265. 10.1046/j.1440-1711.2003.t01-1-01177.x.PubMedCrossRef Moffett JR, Namboodiri MA: Tryptophan and the immune response. Immunol Cell Biol. 2003, 81 (4): 247-265. 10.1046/j.1440-1711.2003.t01-1-01177.x.PubMedCrossRef
2.
go back to reference Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 1993, 45 (3): 309-379.PubMed Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 1993, 45 (3): 309-379.PubMed
3.
go back to reference Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001, 21 (19): 7463-7473.PubMed Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001, 21 (19): 7463-7473.PubMed
4.
go back to reference Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, Bruno JP: Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci. 2009, 29 (3): 529-538. 10.1111/j.1460-9568.2008.06594.x.PubMedCrossRef Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, Bruno JP: Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci. 2009, 29 (3): 529-538. 10.1111/j.1460-9568.2008.06594.x.PubMedCrossRef
5.
go back to reference Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S: Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005, 80 (2-3): 315-322. 10.1016/j.schres.2005.07.013.PubMedCrossRef Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S: Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005, 80 (2-3): 315-322. 10.1016/j.schres.2005.07.013.PubMedCrossRef
6.
go back to reference Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001, 50 (7): 521-530. 10.1016/S0006-3223(01)01078-2.PubMedCrossRef Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001, 50 (7): 521-530. 10.1016/S0006-3223(01)01078-2.PubMedCrossRef
7.
go back to reference Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R: Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 2004, 17 (3): 455-461. 10.1016/j.nbd.2004.07.006.PubMedCrossRef Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R: Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 2004, 17 (3): 455-461. 10.1016/j.nbd.2004.07.006.PubMedCrossRef
8.
go back to reference Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001, 313 (1-2): 96-98. 10.1016/S0304-3940(01)02242-X.PubMedCrossRef Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001, 313 (1-2): 96-98. 10.1016/S0304-3940(01)02242-X.PubMedCrossRef
9.
go back to reference Gabbay V, Klein RG, Katz Y, Mendoza S, Guttman LE, Alonso CM, Babb JS, Hirsch GS, Liebes L: The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry. 51 (8): 935-943. Gabbay V, Klein RG, Katz Y, Mendoza S, Guttman LE, Alonso CM, Babb JS, Hirsch GS, Liebes L: The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry. 51 (8): 935-943.
10.
go back to reference Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007, 98 (1-2): 143-151. 10.1016/j.jad.2006.07.013.PubMedCrossRef Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007, 98 (1-2): 143-151. 10.1016/j.jad.2006.07.013.PubMedCrossRef
11.
go back to reference Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, Leonard BE: Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007, 102 (1-3): 65-72. 10.1016/j.jad.2006.12.008.PubMedCrossRef Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, Leonard BE: Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007, 102 (1-3): 65-72. 10.1016/j.jad.2006.12.008.PubMedCrossRef
12.
go back to reference Miller CL, Llenos IC, Dulay JR, Weis S: Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 1073-1074: 25-37.PubMedCrossRef Miller CL, Llenos IC, Dulay JR, Weis S: Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 1073-1074: 25-37.PubMedCrossRef
13.
go back to reference Olsson SK, Samuelsson M, Saetre P, Lindstrom L, Jonsson EG, Nordin C, Engberg G, Erhardt S, Landen M: Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010, 35 (3): 195-199. 10.1503/jpn.090180.PubMedPubMedCentralCrossRef Olsson SK, Samuelsson M, Saetre P, Lindstrom L, Jonsson EG, Nordin C, Engberg G, Erhardt S, Landen M: Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010, 35 (3): 195-199. 10.1503/jpn.090180.PubMedPubMedCentralCrossRef
14.
go back to reference Asp L, Holtze M, Powell SB, Karlsson H, Erhardt S: Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int J Neuropsychopharmacol. 2009, 1-11. Asp L, Holtze M, Powell SB, Karlsson H, Erhardt S: Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int J Neuropsychopharmacol. 2009, 1-11.
15.
go back to reference Erhardt S, Schwieler L, Emanuelsson C, Geyer M: Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004, 56 (4): 255-260. 10.1016/j.biopsych.2004.06.006.PubMedCrossRef Erhardt S, Schwieler L, Emanuelsson C, Geyer M: Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004, 56 (4): 255-260. 10.1016/j.biopsych.2004.06.006.PubMedCrossRef
16.
go back to reference Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R: Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 35 (8): 1734-1742. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R: Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 35 (8): 1734-1742.
17.
go back to reference Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR: Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res. 210 (1): 84-91. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR: Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res. 210 (1): 84-91.
18.
go back to reference Chess AC, Simoni MK, Alling TE, Bucci DJ: Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007, 33 (3): 797-804. 10.1093/schbul/sbl033.PubMedPubMedCentralCrossRef Chess AC, Simoni MK, Alling TE, Bucci DJ: Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007, 33 (3): 797-804. 10.1093/schbul/sbl033.PubMedPubMedCentralCrossRef
19.
go back to reference Ting KK, Brew BJ, Guillemin GJ: Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation. 2009, 6: 36-10.1186/1742-2094-6-36.PubMedPubMedCentralCrossRef Ting KK, Brew BJ, Guillemin GJ: Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation. 2009, 6: 36-10.1186/1742-2094-6-36.PubMedPubMedCentralCrossRef
20.
go back to reference Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ: The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009, 4 (7): e6344-10.1371/journal.pone.0006344.PubMedPubMedCentralCrossRef Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ: The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009, 4 (7): e6344-10.1371/journal.pone.0006344.PubMedPubMedCentralCrossRef
21.
go back to reference Pfefferkorn ER: Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA. 1984, 81 (3): 908-912. 10.1073/pnas.81.3.908.PubMedPubMedCentralCrossRef Pfefferkorn ER: Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA. 1984, 81 (3): 908-912. 10.1073/pnas.81.3.908.PubMedPubMedCentralCrossRef
22.
go back to reference Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ: Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007, 27 (47): 12884-12892. 10.1523/JNEUROSCI.4101-07.2007.PubMedCrossRef Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ: Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007, 27 (47): 12884-12892. 10.1523/JNEUROSCI.4101-07.2007.PubMedCrossRef
23.
go back to reference Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001, 78 (4): 842-853. 10.1046/j.1471-4159.2001.00498.x.PubMedCrossRef Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001, 78 (4): 842-853. 10.1046/j.1471-4159.2001.00498.x.PubMedCrossRef
24.
go back to reference Gupta SL, Carlin JM, Pyati P, Dai W, Pfefferkorn ER, Murphy MJ: Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infect Immun. 1994, 62 (6): 2277-2284.PubMedPubMedCentral Gupta SL, Carlin JM, Pyati P, Dai W, Pfefferkorn ER, Murphy MJ: Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infect Immun. 1994, 62 (6): 2277-2284.PubMedPubMedCentral
25.
go back to reference Dai W, Pan H, Kwok O, Dubey JP: Human indoleamine 2,3-dioxygenase inhibits Toxoplasma gondii growth in fibroblast cells. J Interferon Res. 1994, 14 (6): 313-317. 10.1089/jir.1994.14.313.PubMedCrossRef Dai W, Pan H, Kwok O, Dubey JP: Human indoleamine 2,3-dioxygenase inhibits Toxoplasma gondii growth in fibroblast cells. J Interferon Res. 1994, 14 (6): 313-317. 10.1089/jir.1994.14.313.PubMedCrossRef
26.
go back to reference Spekker K, Czesla M, Ince V, Heseler K, Schmidt SK, Schares G, Daubener W: Indoleamine 2,3-dioxygenase is involved in defense against Neospora caninum in human and bovine cells. Infect Immun. 2009, 77 (10): 4496-4501. 10.1128/IAI.00310-09.PubMedPubMedCentralCrossRef Spekker K, Czesla M, Ince V, Heseler K, Schmidt SK, Schares G, Daubener W: Indoleamine 2,3-dioxygenase is involved in defense against Neospora caninum in human and bovine cells. Infect Immun. 2009, 77 (10): 4496-4501. 10.1128/IAI.00310-09.PubMedPubMedCentralCrossRef
27.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.PubMedCrossRef Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.PubMedCrossRef
28.
go back to reference Byrne GI, Lehmann LK, Kirschbaum JG, Borden EC, Lee CM, Brown RR: Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res. 1986, 6 (4): 389-396. 10.1089/jir.1986.6.389.PubMedCrossRef Byrne GI, Lehmann LK, Kirschbaum JG, Borden EC, Lee CM, Brown RR: Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res. 1986, 6 (4): 389-396. 10.1089/jir.1986.6.389.PubMedCrossRef
29.
go back to reference Daubener W, MacKenzie CR: IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol. 1999, 467: 517-524. 10.1007/978-1-4615-4709-9_64.PubMedCrossRef Daubener W, MacKenzie CR: IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol. 1999, 467: 517-524. 10.1007/978-1-4615-4709-9_64.PubMedCrossRef
30.
go back to reference King NJ, Thomas SR: Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 2007, 39 (12): 2167-2172. 10.1016/j.biocel.2007.01.004.PubMedCrossRef King NJ, Thomas SR: Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 2007, 39 (12): 2167-2172. 10.1016/j.biocel.2007.01.004.PubMedCrossRef
31.
go back to reference Heyes MP, Chen CY, Major EO, Saito K: Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J. 1997, 326 (Pt 2): 351-356.PubMedPubMedCentralCrossRef Heyes MP, Chen CY, Major EO, Saito K: Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J. 1997, 326 (Pt 2): 351-356.PubMedPubMedCentralCrossRef
32.
go back to reference Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, Mirone P, Masotti G, Moroni F, Tarantini F: Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005, 25 (6): 981-993. 10.1007/s10571-005-8469-y.PubMedCrossRef Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, Mirone P, Masotti G, Moroni F, Tarantini F: Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005, 25 (6): 981-993. 10.1007/s10571-005-8469-y.PubMedCrossRef
33.
go back to reference Kuc D, Rahnama M, Tomaszewski T, Rzeski W, Wejksza K, Urbanik-Sypniewska T, Parada-Turska J, Wielosz M, Turski WA: Kynurenic acid in human saliva--does it influence oral microflora?. Pharmacol Rep. 2006, 58 (3): 393-398.PubMed Kuc D, Rahnama M, Tomaszewski T, Rzeski W, Wejksza K, Urbanik-Sypniewska T, Parada-Turska J, Wielosz M, Turski WA: Kynurenic acid in human saliva--does it influence oral microflora?. Pharmacol Rep. 2006, 58 (3): 393-398.PubMed
34.
go back to reference Wang L, Lockstone HE, Guest PC, Levin Y, Palotas A, Pietsch S, Schwarz E, Rahmoune H, Harris LW, Ma D, Bahn S: Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. J Proteome Res. 2010, 9 (1): 521-527. 10.1021/pr900867x.PubMedCrossRef Wang L, Lockstone HE, Guest PC, Levin Y, Palotas A, Pietsch S, Schwarz E, Rahmoune H, Harris LW, Ma D, Bahn S: Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. J Proteome Res. 2010, 9 (1): 521-527. 10.1021/pr900867x.PubMedCrossRef
35.
go back to reference Mahadik SP, Mukherjee S, Laev H, Reddy R, Schnur DB: Abnormal growth of skin fibroblasts from schizophrenic patients. Psychiatry Res. 1991, 37 (3): 309-320. 10.1016/0165-1781(91)90066-X.PubMedCrossRef Mahadik SP, Mukherjee S, Laev H, Reddy R, Schnur DB: Abnormal growth of skin fibroblasts from schizophrenic patients. Psychiatry Res. 1991, 37 (3): 309-320. 10.1016/0165-1781(91)90066-X.PubMedCrossRef
36.
go back to reference Mahadik SP, Mukherjee S, Wakade CG, Laev H, Reddy RR, Schnur DB: Decreased adhesiveness and altered cellular distribution of fibronectin in fibroblasts from schizophrenic patients. Psychiatry Res. 1994, 53 (1): 87-97. 10.1016/0165-1781(94)90097-3.PubMedCrossRef Mahadik SP, Mukherjee S, Wakade CG, Laev H, Reddy RR, Schnur DB: Decreased adhesiveness and altered cellular distribution of fibronectin in fibroblasts from schizophrenic patients. Psychiatry Res. 1994, 53 (1): 87-97. 10.1016/0165-1781(94)90097-3.PubMedCrossRef
37.
go back to reference Catts VS, Catts SV, McGrath JJ, Feron F, McLean D, Coulson EJ, Lutze-Mann LH: Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines. Schizophr Res. 2006, 84 (1): 20-28. 10.1016/j.schres.2006.03.016.PubMedCrossRef Catts VS, Catts SV, McGrath JJ, Feron F, McLean D, Coulson EJ, Lutze-Mann LH: Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines. Schizophr Res. 2006, 84 (1): 20-28. 10.1016/j.schres.2006.03.016.PubMedCrossRef
38.
go back to reference Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ: Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA. 2007, 104 (42): 16621-16626. 10.1073/pnas.0706778104.PubMedPubMedCentralCrossRef Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ: Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA. 2007, 104 (42): 16621-16626. 10.1073/pnas.0706778104.PubMedPubMedCentralCrossRef
39.
go back to reference Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE: Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 1996, 63 (2-3): 133-142. 10.1016/0165-1781(96)02899-5.PubMedCrossRef Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE: Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 1996, 63 (2-3): 133-142. 10.1016/0165-1781(96)02899-5.PubMedCrossRef
40.
go back to reference Persson ML, Johansson J, Vumma R, Raita J, Bjerkenstedt L, Wiesel FA, Venizelos N: Aberrant amino acid transport in fibroblasts from patients with bipolar disorder. Neurosci Lett. 2009, 457 (1): 49-52. 10.1016/j.neulet.2009.03.095.PubMedCrossRef Persson ML, Johansson J, Vumma R, Raita J, Bjerkenstedt L, Wiesel FA, Venizelos N: Aberrant amino acid transport in fibroblasts from patients with bipolar disorder. Neurosci Lett. 2009, 457 (1): 49-52. 10.1016/j.neulet.2009.03.095.PubMedCrossRef
41.
go back to reference Flyckt L, Venizelos N, Edman G, Bjerkenstedt L, Hagenfeldt L, Wiesel FA: Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. Arch Gen Psychiatry. 2001, 58 (10): 953-958. 10.1001/archpsyc.58.10.953.PubMedCrossRef Flyckt L, Venizelos N, Edman G, Bjerkenstedt L, Hagenfeldt L, Wiesel FA: Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. Arch Gen Psychiatry. 2001, 58 (10): 953-958. 10.1001/archpsyc.58.10.953.PubMedCrossRef
42.
go back to reference Fernell E, Karagiannakis A, Edman G, Bjerkenstedt L, Wiesel FA, Venizelos N: Aberrant amino acid transport in fibroblasts from children with autism. Neurosci Lett. 2007, 418 (1): 82-86. 10.1016/j.neulet.2007.03.004.PubMedCrossRef Fernell E, Karagiannakis A, Edman G, Bjerkenstedt L, Wiesel FA, Venizelos N: Aberrant amino acid transport in fibroblasts from children with autism. Neurosci Lett. 2007, 418 (1): 82-86. 10.1016/j.neulet.2007.03.004.PubMedCrossRef
Metadata
Title
Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts
Authors
Linnéa Asp
Anne-Sofie Johansson
Amandeep Mann
Björn Owe-Larsson
Ewa M Urbanska
Tomasz Kocki
Magdalena Kegel
Göran Engberg
Gabriella BS Lundkvist
Håkan Karlsson
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2011
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-8-25

Other articles of this Issue 1/2011

Journal of Inflammation 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.